|
1
|
Choi WK, Cho DH, Yim CY and Lee NR:
Primary hepatoid carcinoma of the ovary: A case report and review
of the literature. Medicine (Baltimore). 99:e200512020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stamatova D, Theilmann L and Spiegelberg
C: A hepatoid carcinoma of the pancreatic head. Sur Case Rep.
2:782016. View Article : Google Scholar
|
|
3
|
Soofi Y, Kanehira K, Abbas A, Aranez J,
Bain A and Ylagan L: Pancreatic hepatoid carcinoma: A rare form of
pancreatic neoplasm. Diagn Cytopathol. 43:251–256. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen TC, Huang SC, Chang HC, Yeh TS, Ng KF
and Chen TC: Hepatoid microcarcinoma of the pancreas: A case report
and review of the literature. Chang Gung Med J. 35:285–291.
2012.PubMed/NCBI
|
|
5
|
Vanoli A, Argenti F, Vinci A, La Rosa S,
Viglio A, Riboni R, Necchi V, Pugliese L, Sessa F, Pietrabissa A
and Paulli M: Hepatoid carcinoma of the pancreas with lymphoid
stroma: First description of the clinical, morphological,
immunohistochemical, and molecular characteristics of an unusual
pancreatic carcinoma. Virchows Arch. 467:237–245. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zeng SX, Tan SW, Fong CJTH, Liang Q, Zhao
BL, Liu K, Guo J and Tao J: Hepatoid carcinoma of the pancreas: A
case report and review of the literature. World J Clin Cases.
8:1116–1128. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Uribe Rivera AK, Alvarez Larraondo M, Taxa
Rojas L, Bravo Taxa M and Zevallos Cardenas A: Hepatoid carcinoma
of the ovary-A case report and literature review. Gynecol Oncol
Rep. 32:1005642020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Acosta AM and Pins MR: Hepatoid carcinoma
of the ovary: Clinical, histopathologic, and immunophenotypic
features. Arch Pathol Lab Med. 143:883–889. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Karakas Y, Lacin S and Yalcin S: Recent
advances in the management of pancreatic adenocarcinoma. Expert Rev
Anticancer Ther. 18:51–62. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tesfaye AA, Kamgar M, Azmi A and Philip
PA: The evolution into personalized therapies in pancreatic ductal
adenocarcinoma: Challenges and opportunities. Expert Rev Anticancer
Ther. 18:131–148. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tijeras-Raballand A, Hilmi M,
Astorgues-Xerri L, Nicolle R, Bièche I and Neuzillet C: Microbiome
and pancreatic ductal adenocarcinoma. Clin Res Hepatol
Gastroenterol. 45:1015892021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Attiyeh MA, Amini A, Chung V and Melstrom
LG: Multidisciplinary management of locally advanced pancreatic
adenocarcinoma: Biology is King. J Surg Oncol. 123:1395–1404. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ogden J, Xie H, Ma W and Hubbard J: The
management of older adults with pancreatic adenocarcinoma.
Geriatrics. 3:852018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ushio J, Kanno A, Ikeda E, Ando K, Nagai
H, Miwata T, Kawasaki Y, Tada Y, Yokoyama K, Numao N, et al:
Pancreatic ductal adenocarcinoma: Epidemiology and risk factors.
Diagnostics (Basel). 11:5622021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Panchal K, Sahoo RK, Gupta U and
Chaurasiya A: Role of targeted immunotherapy for pancreatic ductal
adenocarcinoma (PDAC) treatment: An overview. Int Immunopharmacol.
95:1075082021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pang Y, Holmes MV, Chen Z and Kartsonaki
C: A review of lifestyle, metabolic risk factors, and blood-based
biomarkers for early diagnosis of pancreatic ductal adenocarcinoma.
J Gastroenterol Hepatol. 34:330–345. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sikdar N, Saha G, Dutta A, Ghosh S,
Shrikhande SV and Banerjee S: Genetic alterations of periampullary
and pancreatic ductal adenocarcinoma: An overview. Curr Genomics.
19:444–463. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Garcia-Carbonero N, Li W, Cabeza-Morales
M, Martinez-Useros J and Garcia-Foncillas J: New Hope for
pancreatic ductal adenocarcinoma treatment targeting endoplasmic
reticulum stress response: A systematic review. Int J Mol Sci.
19:24682018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chappuis PO, Ghadirian P and Foulkes WD:
The role of genetic factors in the etiology of pancreatic
adenocarcinoma: An update. Cancer Inve. 19:65–75. 2001. View Article : Google Scholar
|
|
20
|
Duvillié B, Kourdoughli R, Druillennec S,
Eychène A and Pouponnot C: Interplay between diabetes and
pancreatic ductal adenocarcinoma and insulinoma: The role of aging,
genetic factors, and obesity. Front Endocrinol (Lausanne).
11:5632672020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Eskelinen MJ and Haglund UH: Prognosis of
human pancreatic adenocarcinoma: Review of clinical and
histopathological variables and possible uses of new molecular
methods. Eur J Surg. 165:292–306. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Diaz KE and Lucas AL: Familial pancreatic
ductal adenocarcinoma. Am J Pathol. 189:36–43. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bellotti R, Speth C, Adolph TE, Lass-Flörl
C, Effenberger M, Öfner D and Maglione M: Micro- and mycobiota
dysbiosis in pancreatic ductal adenocarcinoma development. Cancers
(Basel). 13:34312021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bou Zerdan M, Shatila M, Sarwal D,
Bouferraa Y, Bou Zerdan M, Allam S, Ramovic M and Graziano S:
Single cell RNA sequencing: A new frontier in pancreatic ductal
adenocarcinoma. Cancers (Basel). 14:45892022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kothari A and Flick MJ: Coagulation
signaling through PAR1 as a therapeutic target in pancreatic ductal
adenocarcinoma. Int J Mol Sci. 22:51382021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jin T, Dai C and Xu F: Surgical and local
treatment of hepatic metastasis in pancreatic ductal
adenocarcinoma: Recent advances and future prospects. Ther Adv Med
Oncol. 12:1758835920933032020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu X, Gu J, Fu D and Jin C: Dose surgical
resection of hepatic metastases bring benefits to pancreatic ductal
adenocarcinoma? A systematic review and meta-analysis. Int J Surg.
48:149–154. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Parte S, Nimmakayala RK, Batra SK and
Ponnusamy MP: Acinar to ductal cell trans-differentiation: A
prelude to dysplasia and pancreatic ductal adenocarcinoma. Biochim
Biophys Acta Rev Cancer. 1877:1886692022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Igbinigie E, Guo F, Jiang SW, Kelley C and
Li J: Dkk1 involvement and its potential as a biomarker in
pancreatic ductal adenocarcinoma. Clin Chim Acta. 488:226–234.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mere Del Aguila E, Tang XH and Gudas LJ:
Pancreatic ductal adenocarcinoma: New insights into the actions of
vitamin A. Oncol Res Treat. 45:291–298. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Das S and Cardin D: Targeting DNA damage
repair pathways in pancreatic adenocarcinoma. Curr Treat Options
Oncol. 21:622020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Schmitt A, Feldmann G, Zander T and
Reinhardt HC: Targeting defects in the cellular DNA damage response
for the treatment of pancreatic ductal adenocarcinoma. Oncol Res
Treat. 41:619–625. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Qian Y, Gong Y, Fan Z, Luo G, Huang Q,
Deng S, Cheng H, Jin K, Ni Q, Yu X and Liu C: Molecular alterations
and targeted therapy in pancreatic ductal adenocarcinoma. J Hematol
Oncol. 13:1302020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hayashi H, Higashi T, Miyata T, Yamashita
Y and Baba H: Recent advances in precision medicine for pancreatic
ductal adenocarcinoma. Ann Gastroenterol Surg. 5:457–466. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rainone M, Singh I, Salo-Mullen EE,
Stadler ZK and O'Reilly EM: An emerging paradigm for germline
testing in pancreatic ductal adenocarcinoma and immediate
implications for clinical practice: A review. JAMA Oncol.
6:7642020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wu C, Yang P, Liu B and Tang Y: Is there a
CDKN2A-centric network in pancreatic ductal adenocarcinoma? Onco
Targets Ther. 13:2551–2562. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Macchini M, Centonze F, Peretti U, Orsi G,
Militello AM, Valente MM, Cascinu S and Reni M: Epidemiology and
geographic distribution of BRCA1-2 and DNA Damage response genes
pathogenic variants in pancreatic ductal adenocarcinoma patients.
Cancer Treat Rev. 104:1023572022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pimenta JR, Ueda SKN and Peixoto RD:
Excellent response to olaparib in a patient with metastatic
pancreatic adenocarcinoma with germline BRCA1 mutation after
progression on FOLFIRINOX: Case report and literature review. Case
Rep Oncol. 13:904–910. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Rebelatto TF, Falavigna M, Pozzari M,
Spada F, Cella CA, Laffi A, Pellicori S and Fazio N: Should
platinum-based chemotherapy be preferred for germline BReast CAncer
genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma
(PDAC) patients? A systematic review and meta-analysis. Cancer
Treat Rev. 80:1018952019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Reinacher-Schick A, Arnold D, Venerito M,
Goekkurt E, Kraeft AL and Seufferlein T: Platinum-Based
chemotherapy in locally advanced or metastatic pancreatic ductal
adenocarcinoma: Summary of evidence and application in clinical
practice. Oncol Res Treat. 45:752–763. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Singh RR and O'Reilly EM: New treatment
strategies for metastatic pancreatic ductal adenocarcinoma. Drugs.
80:647–669. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zemanek T, Melichar B, Lovecek M, Soucek P
and Mohelnikova-Duchonova B: Biomarkers and pathways of
chemoresistance and chemosensitivity for personalized treatment of
pancreatic adenocarcinoma. Pharmacogenomics. 20:113–127. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Dardare J, Witz A, Merlin JL, Gilson P and
Harlé A: SMAD4 and the TGFβ pathway in patients with pancreatic
ductal adenocarcinoma. Int J Mol Sci. 21:35342020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Jian S, Kong D and Tian J: Expression of
miR-425-5p in pancreatic carcinoma and its correlation with tumor
immune microenvironment. J Invest Surg. 36:22167562023. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Nan P, Dong X, Bai X, Lu H, Liu F, Sun Y
and Zhao X: Tumor-stroma TGF-β1-THBS2 feedback circuit drives
pancreatic ductal adenocarcinoma progression via integrin
αvβ3/CD36-mediated activation of the MAPK pathway. Cancer Lett.
528:59–75. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Rajagopal MU, Bansal S, Kaur P, Jain SK,
Altadil T, Hinzman CP, Li Y, Moulton J, Singh B, Bansal S, et al:
TGFβ drives metabolic perturbations during epithelial mesenchymal
transition in pancreatic cancer: TGFβ induced EMT in PDAC. Cancers
(Basel). 13:62042021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Murthy D, Attri KS and Singh PK:
Phosphoinositide 3-Kinase signaling pathway in pancreatic ductal
adenocarcinoma progression, pathogenesis, and therapeutics. Front
Physiol. 9:3352018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Dolay K, Malya FU and Akbulut S:
Management of pancreatic head adenocarcinoma: From where to where?
World J Gastrointest Surg. 11:143–154. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Vaish U, Jain T, Are AC and Dudeja V:
Cancer-Associated fibroblasts in pancreatic ductal adenocarcinoma:
An update on heterogeneity and therapeutic targeting. Int J Mol
Sci. 22:134082021. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Khokhar AS, Sher AF and Schattner M:
Interventional endoscopy in the diagnosis and management of
pancreatic adenocarcinoma. Chin Clin Oncol. 6:63. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Rémond MS, Pellat A, Brezault C, Dhooge M
and Coriat R: Are targeted therapies or immunotherapies effective
in metastatic pancreatic adenocarcinoma? ESMO Open. 7:1006382022.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Seo YD and Katz MHG: Preoperative therapy
for pancreatic adenocarcinoma-precision beyond anatomy. Cancer.
128:3041–3056. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Lafond M, Lambin T, Drainville RA, Dupré
A, Pioche M, Melodelima D and Lafon C: Pancreatic ductal
adenocarcinoma: Current and emerging therapeutic uses of focused
ultrasound. Cancers (Basel). 14:25772022. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ladd AM and Diehl DL: Artificial
intelligence for early detection of pancreatic adenocarcinoma: The
future is promising. World J Gastroenterol. 27:1283–1295. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Constantin AL, Cazacu IM, Stroescu C,
Copăescu C and Săftoiu A: Prognostic biomarkers related to tumoral
microenvironment in pancreatic ductal adenocarcinoma: A systematic
review. Rom J Morphol Embryol. 62:671–678. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Kulkarni NM, Mannelli L, Zins M, Bhosale
PR, Arif-Tiwari H, Brook OR, Hecht EM, Kastrinos F, Wang ZJ, Soloff
EV, et al: White paper on pancreatic ductal adenocarcinoma from
society of abdominal radiology's disease-focused panel for
pancreatic ductal adenocarcinoma: Part II, update on imaging
techniques and screening of pancreatic cancer in high-risk
individuals. Abdom Radiol (NY). 45:729–742. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Buscail E, Maulat C, Muscari F, Chiche L,
Cordelier P, Dabernat S, Alix-Panabières C and Buscail L: Liquid
biopsy approach for pancreatic ductal adenocarcinoma. Cancers
(Basel). 11:8522019. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Barhli A, Cros J, Bartholin L and
Neuzillet C: Prognostic stratification of resected pancreatic
ductal adenocarcinoma: Past, present, and future. Dig Liver Dis.
50:979–990. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Lupinacci RM, Bachet J-B, André T, Duval A
and Svrcek M: Pancreatic ductal adenocarcinoma harboring
microsatellite instability/DNA mismatch repair deficiency. Towards
personalized medicine. Surg Oncol. 28:121–127. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Leal AD, Messersmith WA and Lieu CH:
Neoadjuvant treatment of localized pancreatic adenocarcinoma. J
Gastrointest Oncol. 12:2461–2474. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Kapszewicz M and Małecka-Wojciesko E:
Simple serum pancreatic ductal adenocarcinoma (PDAC) Protein
Biomarkers-Is There Anything in Sight? J Clin Med. 10:54632021.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Iyengar S, Nevala-Plagemann C and
Garrido-Laguna I: Updates on adjuvant and neoadjuvant treatment
strategies for surgically resectable and borderline resectable
pancreatic ductal adenocarcinoma. Ther Adv Med Oncol.
13:1758835921104582021. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Lawlor R, Veronese N, Nottegar A, Malleo
G, Smith L, Demurtas J, Cheng L, Wood LD, Silvestris N, Salvia R,
et al: Prognostic Role of High-Grade tumor budding in pancreatic
ductal adenocarcinoma: A systematic review and meta-analysis with a
focus on epithelial to mesenchymal transition. Cancers. 11:1132019.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
O'Connor D, Brown M, Eatock M, Turkington
RC and Prue G: Exercise efficacy and prescription during treatment
for pancreatic ductal adenocarcinoma: A systematic review. BMC
Cancer. 21:432021. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Thobie A, Mulliri A, Bouvier V, Launoy G,
Alves A and Dejardin O: Same chance of accessing resection? impact
of socioeconomic status on resection rates among patients with
pancreatic adenocarcinoma-A systematic review. Health Equity.
5:143–150. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
He J, Zhao Q, Liu Q, Li F, He L, Liu M and
Yan X: Surgical resection of pancreatic hepatoid carcinoma followed
by combined transarterial chemoembolization and immunotherapy: A
case report. Onco Targets Ther. 14:4575–4578. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Tomino T, Ninomiya M, Matono R, Narutomi
F, Oshiro Y, Watanabe K, Taniguchi D, Nishimura S, Zaitsu Y,
Kajiwara Y, et al: Pure pancreatic hepatoid carcinoma: A surgical
case report and literature review. Surg Case Rep. 5:1862019.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Zeeshan MS and Ramzan Z: Current
controversies and advances in the management of pancreatic
adenocarcinoma. World J Gastrointest Oncol. 13:472–494. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Gholap NN, Davies MJ, Mostafa SA and
Khunti K: Diagnosing type 2 diabetes and identifying high-risk
individuals using the new glycated haemoglobin (HbA1c) criteria. Br
J Gen Pract. 63:e165–e167. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Trinh HS, Luong TH, Lai TT and Nguyen TK:
Mixed pancreatic hepatoid carcinoma: A surgical case report and
literature review. Int J Surg Case Rep. 83:1059512021. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Cardona D, Grobmyer S, Crawford JM and Liu
C: Hepatocellular carcinoma arising from ectopic liver tissue in
the pancreas. Virchows Arch. 450:225–229. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Kubota K, Kita J, Rokkaku K, Iwasaki Y,
Sawada T, Imura J and Fujimori T: Ectopic hepatocellular carcinoma
arising from pancreas: A case report and review of the literature.
World J Gastroenterol. 13:4270–4273. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Veerankutty FH, Yeldho V, Tu SA, Venugopal
B, Manoj KS and Vidhya C: Hepatoid carcinoma of the pancreas
combined with serous cystadenoma: A case report and review of the
literature. Hepatobiliary Surg Nutr. 4:35462–35362. 2015.PubMed/NCBI
|
|
74
|
Yahaya A, Wa Kammal WS, Abd Shukor N and
Osman SS: Oesophageal hepatoid carcinoma with liver metastasis, a
diagnostic dilemma. Malays J Pathol. 41:59–63. 2019.PubMed/NCBI
|
|
75
|
Schneitler S: Metastasized pancreatic
carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection.
World J Gastroenterol. 21:6384–6390. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Orth M, Metzger P, Gerum S, Mayerle J,
Schneider G, Belka C, Schnurr M and Lauber K: Pancreatic ductal
adenocarcinoma: Biological hallmarks, current status, and future
perspectives of combined modality treatment approaches. Radiat
Oncol. 14:1412019. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Sohal DPS, Kennedy EB, Cinar P, Conroy T,
Copur MS, Crane CH, Garrido-Laguna I, Lau MW, Johnson T,
Krishnamurthi S, et al: Metastatic pancreatic cancer: ASCO
guideline update. J Clin Oncol. JCO20013642020.PubMed/NCBI
|
|
78
|
Brown DB, Gonsalves CF, Yeo CJ, Witkiewicz
AK and Carr BI: One Year survival with poorly differentiated
metastatic pancreatic carcinoma following chemoembolization with
gemcitabine and cisplatin. Oncol Rep. 24:767–769. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Kuo PC, Chen SC, Shyr YM, Kuo YJ, Lee RC
and Wang SE: Hepatoid carcinoma of the pancreas. World J Surg
Oncol. 13:1852015. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Schawkat K, Manning MA, Glickman JN and
Mortele KJ: Pancreatic ductal adenocarcinoma and its variants:
Pearls and perils. Radiographics. 40:1219–1239. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Yang C, Sun L, Lai JZ, Zhou L, Liu Z, Xi
Y, Tao Y, Dooley E and Cao D: Primary hepatoid carcinoma of the
pancreas: A Clinicopathological study of 3 cases with review of
additional 31 cases in the literature. Int J Surg Pathol. 27:28–42.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Al-Obaidy KI, Williamson SR, Shelman N,
Idrees MT and Ulbright TM: Hepatoid teratoma, hepatoid yolk sac
tumor, and hepatocellular carcinoma: A morphologic and
immunohistochemical study of 30 cases. Am J Surg Pathol.
45:127–136. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Su JS, Chen YT, Wang RC, Wu CY, Lee SW and
Lee TY: Clinicopathological characteristics in the differential
diagnosis of hepatoid adenocarcinoma: A literature review. World J
Gastroenterol. 19:321–327. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Lai YCC, Cheng CC, Lai YS and Liu YH:
Cytokeratin 18-associated Histone 3 modulation in hepatocellular
carcinoma: A mini review. Cancer Genomics Proteomics. 14:219–223.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Shimonishi T, Miyazaki K and Nakanuma Y:
Cytokeratin profile relates to histological subtypes and
intrahepatic location of intrahepatic cholangiocarcinoma and
primary sites of metastatic adenocarcinoma of liver.
Histopathology. 37:55–63. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Gurzu S and Jung I: Aberrant pattern of
the cytokeratin 7/cytokeratin 20 immunophenotype in colorectal
adenocarcinomas with BRAF mutations. Pathol Res Pract. 208:163–166.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Yokoyama S, Hamada T, Higashi M, Matsuo K,
Maemura K, Kurahara H, Horinouchi M, Hiraki T, Sugimoto T, Akahane
T, et al: Predicted prognosis of patients with pancreatic cancer by
machine learning. Clin Cancer Res. 26:2411–2421. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Al-Arashi MYH and Byers HR: Cutaneous
clear cell squamous cell carcinoma in situ: Clinical, histological
and immunohistochemical characterization. J Cutan Pathol.
34:226–233. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Miettinen M and Fetsch JF: Distribution of
keratins in normal endothelial cells and a spectrum of vascular
tumors: Implications in tumor diagnosis. Hum Pathol. 31:1062–1067.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Austgulen R, Chedwick L, Vogt Isaksen C,
Vatten L and Craven C: Trophoblast apoptosis in human placenta at
term as detected by expression of a cytokeratin 18 degradation
product of caspase. Arch Pathol Lab Med. 126:1480–1486. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Kuan SF, Montag AG, Hart J, Krausz T and
Recant W: Differential expression of mucin genes in mammary and
extramammary Paget's disease. Am J Surg Pathol. 25:1469–1477. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Kirtonia A, Pandey AK, Ramachandran B,
Mishra DP, Dawson DW, Sethi G, Ganesan TS, Koeffler HP and Garg M:
Overexpression of laminin-5 gamma-2 promotes tumorigenesis of
pancreatic ductal adenocarcinoma through EGFR/ERK1/2/AKT/mTOR
cascade. Cell Mol Life Sci. 79:3622022. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Qazi AM, Gruzdyn O, Semaan A, Seward S,
Chamala S, Dhulipala V, Sethi S, Ali-Fehmi R, Philip PA, Bouwman
DL, et al: Restoration of E-cadherin expression in pancreatic
ductal adenocarcinoma treated with microRNA-101. Surgery.
152:704–713. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Çoban EA, Tecimil D, Kașikci E, Bayrak ÖF
and Şahin F: E-cadherin might be a stage-dependent modulator in
aggressiveness in pancreatic cancer cells. Turk J Biol. 44:230–237.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Hong SM, Li A, Olino K, Wolfgang CL,
Herman JM, Schulick RD, Iacobuzio-Donahue C, Hruban RH and Goggins
M: Loss of E-cadherin expression and outcome among patients with
resectable pancreatic adenocarcinomas. Mod Pathol. 24:1237–1247.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Jiao F, Hu H, Han T, Zhuo M, Yuan C, Yang
H and Wang L and Wang L: Aberrant expression of nuclear HDAC3 and
cytoplasmic CDH1 predict a poor prognosis for patients with
pancreatic cancer. Oncotarget. 7:16505–16516. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Zhao L, Wang YX, Xi M, Liu SL, Zhang P,
Luo LL and Liu MZ: Association between E-cadherin (CDH1)
polymorphisms and pancreatic cancer risk in Han Chinese population.
Int J Clin Exp Pathol. 8:57532015.PubMed/NCBI
|
|
98
|
Saito T, Mizukami H, Umetsu S, Uchida C,
Inaba W, Abe M, Takahashi K, Kudo K, Itabashi C, Yagihashi S and
Hakamada K: Worsened outcome in patients with pancreatic ductal
carcinoma on long-term diabetes: Association with E-cadherin1
(CDH1) promoter methylation. Sci Rep |. 7:180562017. View Article : Google Scholar
|
|
99
|
Dhayat SA, Traeger MM, Rehkaemper J,
Stroese AJ, Steinestel K, Wardelmann E, Kabar I and Senninger N:
Clinical impact of Epithelial-to-Mesenchymal transition regulating
MicroRNAs in pancreatic ductal adenocarcinoma. Cancers (Basel).
10:3282018. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Kang Y, Ling J, Suzuki R, Roife D,
Chopin-Laly X, Truty MJ, Chatterjee D, Wang H, Thomas RM, Katz MH,
et al: SMAD4 regulates cell motility through transcription of
N-Cadherin in human pancreatic ductal epithelium. PLoS One.
9:1079482014. View Article : Google Scholar
|
|
101
|
Ottenhof NA, De Wilde RF, Morsink FH, de
Leng WW, Ausems MG, Morreau H, van Hillegersberg R, Offerhaus GJ
and Milne AN: Pancreatic ductal adenocarcinoma in hereditary
diffuse gastric cancer. A case report. Hum Pathol. 43:457–461.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Zhou L, Sheng WW, Jia C, Shi X, Cao R,
Wang G, Lin Y, Zhu F, Dong Q and Dong M: Musashi2 promotes the
progression of pancreatic cancer through a novel ISYNA1-p21/ZEB-1
pathway. J Cell Mol Med. 24:10560–10572. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Hu D, Ansari D, Pawlowski K, Zhou Q, Sasor
A, Welinder C, Kristl T, Bauden M, Rezeli M, Jiang Y, et al:
Proteomic analyses identify prognostic biomarkers for pancreatic
ductal adenocarcinoma. Oncotarget. 9:9789–9807. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Kurahara H, Takao S, Maemura K, Mataki Y,
Kuwahata T, Maeda K, Ding Q, Sakoda M, Iino S, Ishigami S, et al:
Epithelial-mesenchymal transition and mesenchymal-epithelial
transition via regulation of ZEB-1 and ZEB-2 expression in
pancreatic cancer. J Surg Oncol. 105:655–661. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Vannier C, Mock K, Brabletz T and Driever
W: Zeb1 regulates E-cadherin and Epcam (epithelial cell adhesion
molecule) expression to control cell behavior in early zebrafish
development. J Biol Chem. 288:18643–18659. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Yu C, Wang M, Chen M, Huang Y and Jiang J:
Upregulation of microRNA-138-5p inhibits pancreatic cancer cell
migration and increases chemotherapy sensitivity. Mol Med Rep.
12:5135–5140. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Lerbs T, Bisht S, Schölch S, Pecqueux M,
Kristiansen G, Schneider M, Hofmann BT, Welsch T, Reissfelder C,
Rahbari NN, et al: Inhibition of Six1 affects tumour invasion and
the expression of cancer stem cell markers in pancreatic cancer.
BMC Cancer. 17:2492017. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Lahat G, Lubezky N, Loewenstein S, Nizri
E, Gan S, Pasmanik-Chor M, Hayman L, Barazowsky E, Ben-Haim M and
Klausner JM: Epithelial-to-Mesenchymal transition (EMT) in
intraductal papillary mucinous neoplasm (IPMN) is associated with
high tumor grade and adverse outcomes. Ann Surg Oncol. 21 (Suppl
4):S750–S757. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Blevins MA, Towers CG, Patrick AN, Zhao R
and Ford HL: The SIX1-EYA transcriptional complex as a therapeutic
target in cancer. Expert Opin Ther Targets. 19:213–225. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Nomura A, Majumder K, Giri B, Dauer P,
Dudeja V, Roy S, Banerjee S and Saluja AK: Inhibition of NF-kappa B
pathway leads to deregulation of epithelial-mesenchymal transition
and neural invasion in pancreatic cancer. Lab Invest. 96:1268–1278.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Zaheer A, Wadhwa V, Oh J and Fishman EK:
Pearls and pitfalls of imaging metastatic disease from pancreatic
adenocarcinoma: A systematic review. Clin Imaging. 39:750–758.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Larentzakis A, Anagnostou E, Georgiou K,
Vrakopoulou GZ, Zografos CG, Zografos GC and Toutouzas KG: Place of
hyperthermic intraperitoneal chemotherapy in the armament against
pancreatic adenocarcinoma: A survival, mortality and morbidity
systematic review. Oncol Lett. 21:2462021. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Tao L, Yuan C, Ma Z, Jiang B and Xiu D:
Surgical resection of a primary tumor improves survival of
metastatic pancreatic cancer: A population-based study. Cancer
Manag Res. 9:471–479. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Larentzakis A, Anagnostou E, Georgiou K,
Vrakopoulou GZ, Zografos C, Zografos G and Toutouzas K: Place of
hyperthermic intraperitoneal chemotherapy in the armament against
pancreatic adenocarcinoma: A survival, mortality and morbidity
systematic review. Oncol Lett. 21:2462021. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Brind'Amour A, Webb M, Parapini M, Sidéris
L, Segedi M, Chung SW, Chartier-Plante S, Dubé P, Scudamore CH and
Kim PTW: The role of intraperitoneal chemotherapy in the surgical
management of pancreatic ductal adenocarcinoma: A systematic
review. Clin Exp Metastasis. 38:187–196. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Moletta L, Serafini S, Valmasoni M,
Pierobon ES, Ponzoni A and Sperti C: Surgery for recurrent
pancreatic cancer: Is it effective? Cancers (Basel). 11:9912019.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
La Salvia A, Persano I, Parlagreco E,
Audisio A, Cani M and Brizzi MP: Pancreatic adenocarcinoma and
pancreatic high-grade neuroendocrine carcinoma: Two sides of the
moon. Med Oncol. 39:1682022. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Winner M, Goff SL and Chabot JA:
Neoadjuvant therapy for Non-metastatic pancreatic ductal
adenocarcinoma. Semin Oncol. 42:86–97. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Zhou Y, Liao S, You J and Wu H: Conversion
surgery for initially unresectable pancreatic ductal adenocarcinoma
following induction therapy: A systematic review of the published
literature. Updates Surg. 74:43–53. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Liberko M, Kolostova K, Szabo A, Gurlich
R, Oliverius M and Soumarova R: Circulating tumor cells,
circulating tumor DNA and other blood-based prognostic scores in
pancreatic ductal adenocarcinoma-mini-review. In Vivo. 35:31–39.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Attard JA, Farrugia A, Pathanki A, Roberts
KJ, Dasari B, Isaac J, Ma YT and Chatzizacharias NA: Treatment
strategies for the optimal management of locally advanced
pancreatic adenocarcinoma with curative intent: A systematic
review. Pancreas. 49:1264–1275. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Moorcraft SY, Khan K, Peckitt C, Watkins
D, Rao S, Cunningham D and Chau I: FOLFIRINOX for locally advanced
or metastatic pancreatic ductal adenocarcinoma: The royal marsden
experience. Clin Colorectal Cancer. 13:232–238. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Korrel M, Lof S, Van Hilst J, Alseidi A,
Boggi U, Busch OR, van Dieren S, Edwin B, Fuks D, Hackert T, et al:
Predictors for survival in an international cohort of patients
undergoing distal pancreatectomy for pancreatic ductal
adenocarcinoma. Ann Surg Oncol. 28:1079–1087. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Fancellu A, Petrucciani N, Porcu A, Deiana
G, Sanna V, Ninniri C, Perra T, Celoria V and Nigri G: The impact
on survival and morbidity of Portal-Mesenteric resection during
pancreaticoduodenectomy for pancreatic head adenocarcinoma: A
systematic review and meta-analysis of comparative studies. Cancers
(Basel). 12:19762020. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Chen K, Pan Y, Zhang B, Maher H and Cai X:
Laparoscopic versus open pancreatectomy for pancreatic ductal
adenocarcinoma: A systematic review and meta-analysis. Int J Surg.
53:243–256. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
de Liguori Carino N, O'Reilly DA,
Siriwardena AK, Valle JW, Radhakrishna G, Pihlak R and McNamara MG:
Irreversible Electroporation in pancreatic ductal adenocarcinoma:
Is there a role in conjunction with conventional treatment? Eur J
Surg Oncol. 44:1486–1493. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Yang DJ, Xiong JJ, Lu HM, Wei Y, Zhang L,
Lu S and Hu WM: The oncological safety in minimally invasive versus
open distal pancreatectomy for pancreatic ductal adenocarcinoma: A
systematic review and meta-analysis. Sci Rep. 9:11592019.
View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Ferreira BP, Vasquez J and Carilli A:
Metastatic hepatoid carcinoma of the pancreas: First description of
treatment with capecitabine and temozolomide. Am J Med Sci.
353:610–612. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Brunner M, Wu Z, Krautz C, Pilarsky C,
Grützmann R and Weber GF: Current clinical strategies of pancreatic
cancer treatment and open molecular questions. Int J Mol Sci.
20:45432019. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Oba A, Ho F, Bao QR, Al-Musawi MH,
Schulick RD and Del Chiaro M: Neoadjuvant treatment in pancreatic
cancer. Front Oncol. 10:2452020. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Varghese AM, Lowery MA, Yu KH and O'Reilly
EM: Current management and future directions in metastatic
pancreatic adenocarcinoma: Review of metastatic pancreatic
adenocarcinoma. Cancer. 122:3765–3775. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Duffy A and Kummar S: Metastatic
pancreatic adenocarcinoma: Current standards, future directions. Am
J Ther. 17:79–85. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Akhuba L, Tigai Z and Shek D: Where do we
stand with immunotherapy for advanced pancreatic ductal
adenocarcinoma: A synopsis of clinical outcomes. Biomedicines.
10:31962022. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Sendur M: Current treatment options for
metastatic pancreatic adenocarcinoma. UHOD. 25:263–274. 2015.
View Article : Google Scholar
|
|
135
|
Conroy T and Mitry E: Chemotherapy of
metastatic pancreatic adenocarcinoma: Challenges and encouraging
results. Bull Cancer. 98:1439–1446. 2011.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Ballehaninna UK and Chamberlain RS: The
clinical utility of serum CA 19-9 in the diagnosis, prognosis and
management of pancreatic adenocarcinoma: An evidence based
appraisal. J Gastrointest Oncol. 3:105–119. 2012.PubMed/NCBI
|
|
137
|
Kriz D, Ansari D and Andersson R:
Potential biomarkers for early detection of pancreatic ductal
adenocarcinoma. Clin Transl Oncol. 22:2170–2174. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Wu H, Ou S, Zhang H, Huang R, Yu S, Zhao M
and Tai S: Advances in biomarkers and techniques for pancreatic
cancer diagnosis. Cancer Cell Int. 22:2202022. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Brand RE, Nolen BM, Zeh HJ, Allen PJ,
Eloubeidi MA, Goldberg M, Elton E, Arnoletti JP, Christein JD,
Vickers SM, et al: Serum biomarker panels for the detection of
pancreatic cancer. Clin Cancer Res. 17:805–816. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Tartaglione S, Pecorella I, Zarrillo SR,
Granato T, Viggiani V, Manganaro L, Marchese C, Angeloni A and
Anastasi E: Protein Induced by Vitamin K Absence II (PIVKA-II) as a
potential serological biomarker in pancreatic cancer: A pilot
study. Biochem Med (Zagreb). 29:0207072019. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Tartaglione S, Mancini P, Viggiani V,
Chirletti P, Angeloni A and Anastasi E: PIVKA-II: A biomarker for
diagnosing and monitoring patients with pancreatic adenocarcinoma.
PLoS One. 16:e02516562021. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Chan HLY, Vogel A, Berg T, De Toni EN,
Kudo M, Trojan J, Eiblmaier A, Klein HG, Hegel JK, Sharma A, et al:
Performance evaluation of the Elecsys PIVKA-II and Elecsys AFP
assays for hepatocellular carcinoma diagnosis. JGH Open. 6:292–300.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Okada KI, Kawai M, Tani M, Hirono S,
Miyazawa M, Shimizu A, Kitahata Y and Yamaue H: Predicting factors
for unresectability in patients with pancreatic ductal
adenocarcinoma. J Hepatobiliary Pancreat Sci. 21:648–653. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Ozaki K, Hayashi H, Ikuta Y, Masuda T,
Akaboshi S, Ogata K, Matumoto K, Ogawa K, Kamio T, Baba H and
Takamori H: Conversion surgery for initially unresectable
pancreatic ductal adenocarcinoma with synchronous liver metastasis
after treatment with FOLFIRINOX. Clin J Gastroenterol. 12:603–608.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Sunagawa Y, Yamada S, Sato Y, Morimoto D,
Sonohara F, Takami H, Inokawa Y, Hayashi M, Kanda M, Tanaka C, et
al: Novel prognostic implications of DUPAN-2 in the era of initial
systemic therapy for pancreatic cancer. Ann Surg Oncol.
27:2081–2089. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Takagi T, Nagai M, Nishiwada S, Terai T,
Yasuda S, Matsuo Y, Doi S, Kohara Y and Sho M: Importance of triple
tumor markers as biomarkers in patients with pancreatic ductal
adenocarcinoma. Ann Gastroenterol Surg. 7:326–335. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Hosokawa Y, Nagakawa Y, Sahara Y,
Takishita C, Katsumata K and Tsuchida A: Serum SPan-1 is a
significant risk factor for early recurrence of pancreatic cancer
after curative resection. Dig Surg. 34:125–132. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Nishio K, Kimura K, Amano R, Yamazoe S,
Ohrira G, Nakata B, Hirakawa K and Ohira M: Preoperative predictors
for early recurrence of resectable pancreatic cancer. World J Surg
Oncol. 15:162017. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Tsutsumi K, Kawamoto H, Hirao K,
Sakakihara I, Yamamoto N, Noma Y, Fujii M, Kato H, Ogawa T, Ishida
E, et al: Monitoring of CA19-9 and SPan-1 can facilitate the
earlier confirmation of progressing pancreatic cancer during
chemotherapy. Pancreatology. 12:409–416. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Shimizu T, Asakuma M, Tomioka A, Inoue Y,
Hirokawa F, Hayashi M and Uchiyama K: Span-1 and CA19-9 as
predictors of early recurrence and lymph node metastasis for
patients with invasive pancreatic cancer after pancreatectomy. Am
Surg. 84:109–113. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Inokuchi S, Itoh S, Yoshizumi T, Yugawa K,
Yoshiya S, Toshima T, Takeishi K, Iguchi T, Sanefuji K, Harada N,
et al: Mitochondrial expression of the DNA repair enzyme OGG1
improves the prognosis of pancreatic ductal adenocarcinoma.
Pancreatology. 20:1175–1182. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Miyata T, Hayashi H, Yamashita YI,
Matsumura K, Nakao Y, Itoyama R, Yamao T, Tsukamoto M, Okabe H,
Imai K, et al: Prognostic value of the preoperative tumor marker
index in resected pancreatic ductal adenocarcinoma: A retrospective
single-institution study. Ann Surg Oncol. 28:1572–1580. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Ishido K, Kimura N, Wakiya T, Nagase H,
Hara Y, Kanda T, Fujita H and Hakamada K: Development of a
biomarker-based scoring system predicting early recurrence of
resectable pancreatic duct adenocarcinoma. Ann Surg Oncol.
29:1281–1293. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Kondo N, Murakami Y, Uemura K, Nakagawa N,
Takahashi S, Ohge H and Sueda T: Comparison of the prognostic
impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II
levels in patients with pancreatic carcinoma. Pancreatology.
17:95–102. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Ho J, Li X, Zhang L, Liang Y, Hu W, Yau
JCW, Chan H, Gin T, Chan MTV, Tse G and Wu WKK: Translational
genomics in pancreatic ductal adenocarcinoma: A review with
re-analysis of TCGA dataset. Semin Cancer Biol. 55:70–77. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Pietrasz D, Sereni E, Lancelotti F, Pea A,
Luchini C, Innamorati G, Salvia R and Bassi C: Circulating tumour
DNA: A challenging innovation to develop ‘precision onco-surgery’
in pancreatic adenocarcinoma. Br J Cancer. 126:1676–1683. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
157
|
McGowan R, Sally Á, McCabe A, Moran BM and
Finn K: Circulating nucleic acids as novel biomarkers for
pancreatic ductal adenocarcinoma. Cancers (Basel). 14:20272022.
View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Araujo RLC, Silva RO, de Pádua Souza C,
Milani JM, Huguet F, Rezende AC and Gaujoux S: Does neoadjuvant
therapy for pancreatic head adenocarcinoma increase postoperative
morbidity? A systematic review of the literature with
meta-analysis. J Surg Oncol. 121:881–892. 2020.PubMed/NCBI
|
|
159
|
Taniere P, Borghi-Scoazec G, Saurin JC,
Lombard-Bohas C, Boulez J, Berger F, Hainaut P and Scoazec JY:
Cytokeratin expression in adenocarcinomas of the esophagogastric
junction: A comparative study of adenocarcinomas of the distal
esophagus and of the proximal stomach. Am J Surg Pathol.
26:1213–1221. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Kim MA, Lee HS, Yang H-K and Kim WH:
Cytokeratin expression profile in gastric carcinomas. Hum Pathol.
35:576–581. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Xu W, Zhang MW, Huang J, Wang X, Xu SF, Li
Y and Wang SJ: Correlation between CK18 gene and gastric carcinoma
micrometastasis. World J Gastroenterol. 11:6530–6534. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Chen ZM and Wang HL: Alteration of
cytokeratin 7 and cytokeratin 20 expression profile is uniquely
associated with tumorigenesis of primary adenocarcinoma of the
small intestine. Am J Surg Pathol. 28:1352–1359. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Kelder W, van den Berg A, van der Leij J,
Bleeker W, Tiebosch AT, Grond JK, Baas PC and Plukker JT: RT-PCR
and immunohistochemical evaluation of sentinel lymph nodes after in
vivo mapping with Patent Blue V in colon cancer patients. Scand J
Gastroenterol. 41:1073–1078. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Athanassiadou P, Psyhoyiou H, Grapsa D,
Gonidi M, Ketikoglou I and Patsouris E: Cytokeratin 8 and 18
expression in imprint smears of chronic viral hepatitis, autoimmune
hepatitis and hepatocellular carcinoma. Acta Cytologica. 51:61–65.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Terracciano LM, Glatz K, Mhawech P, Vasei
M, Lehmann FS, Vecchione R and Tornillo L: Hepatoid adenocarcinoma
with liver metastasis mimicking hepatocellular carcinoma: An
immunohistochemical and molecular study of eight cases. Am J Surg
Pathol. 27:1302–1312. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Cabibi D, Licata A, Barresi E, Craxì A and
Aragona F: Expression of cytokeratin 7 and 20 in pathological
conditions of the bile tract. Pathol Res Pract. 199:65–70. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Castrillon DH, Lee KR and Nucci MR:
Distinction between endometrial and endocervical adenocarcinoma: An
immunohistochemical study. Int J Gynecol Pathol. 21:4–10. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Chu P, Wu E and Weiss LM: Cytokeratin 7
and cytokeratin 20 expression in epithelial neoplasms: A survey of
435 cases. Mod Pathol. 13:962–972. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Vang R, Gown AM, Barry TS, Wheeler DT,
Yemelyanova A, Seidman JD and Ronnett BM: Cytokeratins 7 and 20 in
primary and secondary mucinous tumors of the ovary: Analysis of
coordinate immunohistochemical expression profiles and staining
distribution in 179 cases. Am J Surg Pathol. 30:1130–1139. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Harnden P, Kennedy W, Andrew AC and
Southgate J: Immunophenotype of transitional metaplasia of the
uterine cervix. Int J Gynecol Pathol. 18:125–129. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Tot T: Patterns of distribution of
cytokeratins 20 and 7 in special types of invasive breast
carcinoma: a study of 123 cases. Ann Diagn Pathol. 3:350–356. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Cruz I, Ciudad J, Cruz JJ, Ramos M,
Gómez-Alonso A, Adansa JC, Rodríguez C and Orfao A: Evaluation of
multiparameter flow cytometry for the detection of breast cancer
tumor cells in blood samples. Am J Clin Pathol. 123:66–74. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Leivo I: Sinonasal adenocarcinoma: Update
on classification, immunophenotype and molecular features. Head
Neck Pathol. 10:68–74. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Bejarano PA, Nikiforov YE, Swenson ES and
Biddinger PW: Thyroid transcription factor-1, thyroglobulin,
cytokeratin 7, and cytokeratin 20 in thyroid neoplasms. Appl
Immunohistochem Mol Morphol. 8:189–194. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Ikeda S, Fujimori M, Shibata S, Okajima M,
Ishizaki Y, Kurihara T, Miyata Y, Iseki M, Shimizu Y, Tokumoto N,
et al: Combined immunohistochemistry of beta-catenin, cytokeratin
7, and cytokeratin 20 is useful in discriminating primary lung
adenocarcinomas from metastatic colorectal cancer. BMC Cancer.
6:312006. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Mhawech P, Uchida T and Pelte MF:
Immunohistochemical profile of high-grade urothelial bladder
carcinoma and prostate adenocarcinoma. Hum Pathol. 33:1136–1140.
2002. View Article : Google Scholar : PubMed/NCBI
|
